NewEdge Advisors’s Cardiff Oncology CRDF Stock Holding History

NewEdge Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105	Hold	81	–	–	﹤0.01%	4144
2026 Q1	$131	Hold	81	–	–	﹤0.01%	4077
2025 Q4	$228	Hold	81	–	–	﹤0.01%	4124
2025 Q3	$167	Hold	81	–	–	﹤0.01%	4014
2025 Q2	$255	Hold	81	–	–	﹤0.01%	3867
2025 Q1	$254	Hold	81	–	–	﹤0.01%	3780
2024 Q4	$352	Hold	81	–	–	﹤0.01%	3701
2024 Q3	$216	Hold	81	–	–	﹤0.01%	3677
2024 Q2	$180	Hold	81	–	–	﹤0.01%	3655
2024 Q1	$433	Hold	81	–	–	﹤0.01%	3600
2023 Q4	$120	Hold	81	–	–	﹤0.01%	3632
2023 Q3	$113	Hold	81	–	–	﹤0.01%	3364
2023 Q2	$119	Hold	81	–	–	﹤0.01%	3415
2023 Q1	$134	Hold	81	–	–	﹤0.01%	3330
2022 Q4	$0	Buy	+81	New	+$116	﹤0.01%	4107

Other funds holding CRDF

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NewEdge Advisors's CRDF Position: Q2 2026 in Review

NewEdge Advisors held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 81 shares worth $105. The position accounts for ﹤0.01% of the portfolio, ranked #4144.

NewEdge Advisors first reported a position in CRDF in Q4 2022 and has held it in 15 quarters since. The position peaked at $433 in Q1 2024. 80 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

NewEdge Advisors held 81 shares of Cardiff Oncology worth $105 as of Q2 2026.
NewEdge Advisors left its Cardiff Oncology share count unchanged in Q2 2026.
Cardiff Oncology made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4144 holding.
NewEdge Advisors first reported a position in Cardiff Oncology in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's Cardiff Oncology position peaked at $433 in Q1 2024.
80 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.